Medtronic (NYSE:MDT) announced today that it expanded U.S. pharmacy formulary access for its MiniMed 780G insulin pump.

Medtronic has recalled some of its insulin pumps after injuries and one death were reported due to the device malfunctioning, according to a US Food and Drug Administration announcement on Wednesday.

After a long delay, the U.S. Food and Drug Administration has approved Medtronic's MiniMed 780G device, the company's next-generation insulin pump. Medtronic's diabetes division has been under a ...

Just a few months after Medtronic resolved a late 2021 FDA warning letter describing quality control issues at the headquarters of its diabetes division, that segment of its business is in the hot ...

Medtronic has secured a new approval in Europe, greatly expanding the reach of its MiniMed 780G pump system—including for people with Type 2 diabetes who require insulin. The CE mark also opens it up ...

Medtronic disclosed Diabetes unit executive pay packages for 2025 and compensation targets for when they'll lead MiniMed as a ...